Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: Results of a Prospective Trial. Report No. 2

Chunhua Jiao; Dean Eliott; Christine Spee; Shikun He; Kai Wang; Robert F Mullins; David R Hinton; Elliott H Sohn

doi:10.1097/IAE.0000000000001952

Back

Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: Results of a Prospective Trial. Report No. 2

Journal article

Peer reviewed

Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: Results of a Prospective Trial. Report No. 2

Chunhua Jiao, Dean Eliott, Christine Spee, Shikun He, Kai Wang, Robert F Mullins, David R Hinton and Elliott H Sohn

Retina (Philadelphia, Pa.), Vol.39(2), pp.265-273

02/01/2019

DOI: 10.1097/IAE.0000000000001952

PMID: 29190236

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/5963961View

Open Access

Abstract

We sought to characterize the angiofibrotic and apoptotic effects of vascular endothelial growth factor (VEGF)-inhibition on fibrovascular epiretinal membranes in eyes with traction retinal detachment because of proliferative diabetic retinopathy. Membranes were excised from 20 eyes of 19 patients (10 randomized to intravitreal bevacizumab, 10 controls) at vitrectomy. Membranes were stained with antibodies targeting connective tissue growth factor (CTGF) or VEGF and colabeled with antibodies directed against endothelial cells (CD31), myofibroblasts, or retinal pigment epithelium markers. Quantitative and colocalization analyses of antibody labeling were obtained through immunofluorescence confocal microscopy. Masson trichrome staining, cell counting of hematoxylin and eosin sections, and terminal dUTP nick-end labeling staining were performed. High levels of fibrosis were observed in both groups. Cell apoptosis was higher (P = 0.05) in bevacizumab-treated membranes compared with controls. The bevacizumab group had a nonsignificant reduction in colocalization in CD31-CTGF and cytokeratin-VEGF studies compared with controls. Vascular endothelial growth factor in extracted membranes was positively correlated with vitreous levels of VEGF; CTGF in extracted membranes was negatively correlated with vitreous levels of CTGF. Bevacizumab suppresses vitreous VEGF levels, but does not significantly alter VEGF or CTGF in diabetic membranes that may be explained by high baseline levels of fibrosis. Bevacizumab may cause apoptosis within fibrovascular membranes.

Details

Title: Subtitle: Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: Results of a Prospective Trial. Report No. 2
Creators: Chunhua Jiao - University of Iowa, Ophthalmology and Visual Sciences
Dean Eliott - Harvard Medical School
Christine Spee - University of Southern California
Shikun He - University of Southern California
Kai Wang - University of Iowa, Biostatistics
Robert F Mullins - University of Iowa, Ophthalmology and Visual Sciences
David R Hinton - University of Southern California
Elliott H Sohn - University of Iowa, Ophthalmology and Visual Sciences
Resource Type: Journal article
Publication Details: Retina (Philadelphia, Pa.), Vol.39(2), pp.265-273
DOI: 10.1097/IAE.0000000000001952
PMID: 29190236
NLM abbreviation: Retina
ISSN: 0275-004X
eISSN: 1539-2864
Publisher: United States
Language: English
Date published: 02/01/2019
Academic Unit: Biostatistics; Ophthalmology and Visual Sciences
Record Identifier: 9983607200302771

Metrics

27 Record Views

20 Times Cited - Web of Science